Cytokinetics CYTK Liabilities Related To RPI Transactions Fairvalue
Liabilities Related To RPI Transactions Fairvalue at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept cytk:LiabilitiesRelatedToRPITransactionsFairvalue.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's liabilities related to rpi transactions fairvalue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's liabilities related to RPI transactions fairvalue?
- Cytokinetics (CYTK) reported liabilities related to RPI transactions fairvalue of $138.8M in Q1 2026.
- How has Cytokinetics's liabilities related to RPI transactions fairvalue changed year-over-year?
- Cytokinetics's liabilities related to RPI transactions fairvalue increased by 4.3% year-over-year, from $133.1M to $138.8M.
- What does liabilities related to RPI transactions fairvalue mean?
- The estimated value of future revenue shares owed to investors who funded development.
- How do you interpret liabilities related to RPI transactions fairvalue?
- An increase reflects higher expected future royalty payouts or new financing deals, while a decrease suggests payments made or revaluation of the liability.
- How does liabilities related to RPI transactions fairvalue compare across companies?
- Common in clinical-stage biotechs using non-dilutive financing to fund expensive drug trials.